<i>In Silico</i>
            Verification and Parallel Reaction Monitoring Prevalidation of Potential Prostate Cancer Biomarkers

Adeola, Henry Ademola; Calder, Bridget; Soares, Nelson C.; Kaestner, Lisa; Blackburn, Jonathan M.; Zerbini, Luiz F.

doi:10.2217/fon.15.296

Cited by 14 publications

(15 citation statements)

References 43 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The “triple quadrupole” is a cascade of quads, the first performs m/z sorting, the second fragments ions from the first filtering stage, while the third quad selects specific fragmentation products generated [37] .…”

Section: Proteomics Discovery Platforms Used In Prostate Cancer Biomamentioning

confidence: 99%

See 1 more Smart Citation

Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery

et al. 2017

View full text Add to dashboard Cite

The clinical and fundamental research in prostate cancer - the most common urological cancer in men - is currently entering the proteomic and genomic era. The focus has switched from one single marker (PSA) to panels of biomarkers (including proteins involved in ribosomal function and heat shock proteins). Novel genetic markers (such as Transmembrane protease serine 2 (TMPRSS2)-ERG fusion gene mRNA) or prostate cancer gene 3 (PCA3) had already entered the clinical practice, raising the question whether subsequent protein changes impact the evolution of the disease and the response to treatment. Proteomic technologies such as MALDI-MS, SELDI-MS, i-TRAQ allow a qualitative/quantitative analysis of the proteome variations, in both serum and tumor tissue. A new trend in prostate cancer research is proteomic analysis of prostasomes (prostate-specific exosomes), for the discovery of new biomarkers. This paper provides an update of novel clinical tests used in research and clinical diagnostic, as well as of potential tissue or fluid biomarkers provided by extensive proteomic research data.

show abstract

Section: Proteomics Discovery Platforms Used In Prostate Cancer Biomamentioning

confidence: 99%

“…SRM-MS (Single Reaction Monitoring) was used for discovery and validation of cancer biomarkers in serum [38], including PCa biomarkers [39, 40], as well as the MRM-MS approach (Multiple Reaction Monitoring - MS [37]. …”

Section: Proteomics Discovery Platforms Used In Prostate Cancer Biomamentioning

confidence: 99%

Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Of the 12 potential biomarkers found, several were found in the urine of both normal patients and patients with prostate cancer, insinuating that proteomic urinalysis is not infallible. The protein HPR is more commonly found in the urine of patients with prostate cancer, though it has been found in one healthy individual in the study [29]. In another study, conducted by Percy et al described that 136 proteins, of greater than five order of magnitude, found in urine can be applied to prostate cancer samples, a possible means of diagnosis [30].…”

Section: Proteomics In Urologymentioning

confidence: 82%

Future of Urological Diagnosis Using Proteomics: A Review of Literature

Dagur¹,

Jason²,

hi³

et al. 2016

Transl Biomed

View full text Add to dashboard Cite

Proteomics is a large-scale study of proteins. Several technologies are used to isolate and identify proteins of various spectra, which is useful in differentiating complexity of proteins. Critical role of proteomics can be applied to the field of urology, as a means of noninvasive biomarkers to diagnose patients with benign and malignant nephro-urological diseases. The accuracy of proteomic analysis findings in predicting specific clinical pathologies continues to draw controversy, thus further studies are necessary to confirm the diagnosis. Future of diagnosis in urology is expected to be done by proteomic urinalysis.

show abstract

“…Among these 82 identified biomarkers, nine biomarkers were identified that suggested racial differences among the ethnicities in the cohort. Verification and prevalidation of the 82 biomarkers using both experimental ‘parallel reaction monitoring’ and in silico computational methods enabled identification of the top performing 12 potential biomarkers [90], ready for translation through a large scale, multiplatform and multicenter targeted proteomics validation study. Furthermore, relating to the ability of cancers to stimulate humoral immune response in the body, 41 novel potential serological autoantibody profiles have been identified in a South African PCa patient cohort ( N = 67) [91].…”

Section: Proteomics Biomarker Discovery In Africamentioning

confidence: 99%

“…In silico prevalidation is required in early phase of biomarkers development study [21, 90], to optimize potential biomarkers prior to large scale studies. The cost implication and infrastructure needed for large scale validation of omics based biomarkers can be prohibitive [125], hence collaborative efforts such as the EDRN are necessary to achieve this goal [98].…”

Section: Challenges and Prospects Of Pca Proteomics Biomarker Discovementioning

confidence: 99%

Emerging proteomics biomarkers and prostate cancer burden in Africa

et al. 2017

View full text Add to dashboard Cite

Various biomarkers have emerged via high throughput omics-based approaches for use in diagnosis, treatment, and monitoring of prostate cancer. Many of these have yet to be demonstrated as having value in routine clinical practice. Moreover, there is a dearth of information on validation of these emerging prostate biomarkers within African cohorts, despite the huge burden and aggressiveness of prostate cancer in men of African descent. This review focusses of the global landmark achievements in prostate cancer proteomics biomarker discovery and the potential for clinical implementation of these biomarkers in Africa. Biomarker validation processes at the preclinical, translational and clinical research level are discussed here, as are the challenges and prospects for the evaluation and use of novel proteomic prostate cancer biomarkers.

show abstract

In Silico Verification and Parallel Reaction Monitoring Prevalidation of Potential Prostate Cancer Biomarkers

Abstract: The pragmatic penultimate screening step, described herein, would immensely improve targeted proteomics validation of potential disease biomarkers.

Cited by 14 publications

References 43 publications

Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery

Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery

Future of Urological Diagnosis Using Proteomics: A Review of Literature

Emerging proteomics biomarkers and prostate cancer burden in Africa

Contact Info

Product

Resources

About